Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Procter & Gamble has agreed to acquire premium supplement maker Thorne from L Catterton in an all-cash transaction valued at $3.8 billion, extending its push into faster-growing health and wellness categories.</li><li>The transaction, which is expected to close in the fourth quarter of 2026, follows reported interest from other consumer-health groups, including Haleon and Unilever.</li><li>Thorne, founded in 1984, sells science-backed supplements spanning creatine, prenatal vitamins and other preventive-health applications, and was reportedly on track to generate approximately $650 million in 2026 sales.</li></ul>

Procter & Gamble has agreed to acquire premium supplement maker Thorne from L Catterton in an all-cash transaction valued at $3.8 billion, extending its push into faster-growing health and wellness categories.The transaction, which is expected to close in the fourth quarter of 2026, follows reported interest from other consumer-health groups, including Haleon and Unilever.Thorne, founded in 1984, sells science-backed supplements spanning creatine, prenatal vitamins and other preventive-health applications, and was reportedly on track to generate approximately $650 million in 2026 sales.

P&G’s $3.8 Billion Thorne Acquisition Could Reshape Wellness!

Procter & Gamble Co

P&G’s $3.8 Billion Thorne Acquisition Could Reshape Wellness!